FindMyKOL
Clinical trialNCT05785845CompletedInterventional

Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer

NCT05785845 is an interventional trial sponsored by Washington University School of Medicine. As of 21 Nov 2026, it is completed. It studies Early Stage Non-small Cell Lung Cancer and Non-small Cell Lung Cancer. The registry lists an enrollment of 17 participants at 1 site in 1 country. The registry lists a start date of 10 Apr 2023 and a primary completion date of 2 Jun 2026. One of its registered investigators has a FindMyKOL profile.

SponsorWashington University School of Medicine →Enrollment17Early Stage Non-small Cell Lung CancerNon-small Cell Lung Cancer
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05785845
FieldValue
Registry IDNCT05785845
StatusCompleted
Study typeInterventional trial
Lead sponsorWashington University School of Medicine
Enrollment17
Registered sites1
Countries1
ConditionsEarly Stage Non-small Cell Lung Cancer and Non-small Cell Lung Cancer
Start10 Apr 2023
Primary completion2 Jun 2026
Study completion2 Jun 2026
Last update posted6 Aug 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will evaluate the impact of CT-guided adaptive stereotactic radiotherapy (CT-STAR) to central and ultra-central early-stage non-small cell lung cancers on grade 3 or greater toxicity. Online adaptive radiation therapy was until recently only done clinically on an integrated MRI-guided system, but recently, Varian Medical Systems has created a CT-guided radiotherapy machine capable of online adaptive radiotherapy (ETHOS). The vast majority of stereotactic body radiotherapy (SBRT) for early-stage lung cancers is performed on a CT-guided machine rather than an MRI-guided machine, necessitating the evaluation of adaptive radiotherapy using ETHOS in this population. Historically, the non-adaptive, stereotactic treatment of central and ultra-central thoracic disease has been associated with unacceptable rates of grade 3+ toxicity. This has resulted in widespread adoption of a hypofractionated, less ablative 8-15 day treatment courses, with a baseline, one-year grade 3+ toxicity rate of 20%. Use of CT-STAR with daily, CT-guided plan adaptation to carefully spare adjacent organs-at-risk (OAR) in this setting may enable safe delivery of a shorter (5 fraction) and more ablative radiotherapy course.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Missouri, United States1 site
  • Washington University School of Medicine

    St Louis

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouri: 1 siteMO1KentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT05785845

Each answer restates registry values shown on this page.

What is NCT05785845?

NCT05785845 is an interventional trial sponsored by Washington University School of Medicine. It studies Early Stage Non-small Cell Lung Cancer and Non-small Cell Lung Cancer.

Who leads NCT05785845?

The registry names Pamela Samson, M.D., MPHS (principal investigator, Washington University School of Medicine) as the overall official.

Where does NCT05785845 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

When did NCT05785845 end?

The registry lists a primary completion date of 2 Jun 2026 and a study completion date of 2 Jun 2026. The sponsor last updated the record on 6 Aug 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.